Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

BioInvent is a research-based pharmaceutical company developing innovative antibody drugs targeting cancers with unmet clinical need.Our drug development programmes are supported by our human antibody development platform. This consists of a proprietary antibody library, n-CoDeR:registered:, and in-house technology for the rapid selection, screening and identification of antibodies with excellent affinity and selectivity for targets. BioInvent has a high level of competence in antibody drug discovery, preclinical and clinical development. The Company also has many years' experience in process development and antibody manufacturing, which we carry out at our own facilities. Alongside our in house and partnered drug-development programmes we offer antibody discovery and development services to customers. BioInvent's business model and technology platform have been validated through numerous partnerships. These include a co-development agreement with Bayer, Daiichi Sankyo, Mitsubishi Tanabe, Servier and others. BioInvent employs around 50 people and is based in Lund, Sweden. The Company listed on the NASDAQ OMX Stockholm in 2001.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Merck Sharp & Dohme LLC, part of Merck & Co., Inc., is a company headquartered in Kenilworth, NJ, that operates as a pharmaceutical company.

Acambis Research Ltd. is a British joint venture company located in Reading that engages in research and experimental development on natural sciences and engineering. It was founded in 1992.

Forskarpatent i Syd AB specialises in the commercialisation, through licensing or new venture spinouts, of patentable inventions emanating mainly from Swedish universities. It holds a portfolio of projects in the format of shares in spinouts, partnered (licensed) and still unpartnered assets. It is involves in projects in pharmaceutical, technology, and food categories. The firm is categorized under patent agency operations. The company was founded on January 18, 1996 and is headquartered in Lund, Sweden.

They are founded in 2012 by three entrepreneurial scientists, hoping to devise a full-proof platform for the discovery of clinically-relevant antibodies. Over the years, they have been supported by many prestigious entrepreneurship and scientific awards to create our Nebula Antibody platform and have substantiated this platform through several collaborations with various North American and European pharmaceutical partners. We have also produced over 350 commercial antibodies and submitted several patents for our technologies. In 2015, they took the bold step of initiating their own antibody pipeline, with a primary focus on cancer and gastrointestinal health. Thus far we have advanced 4 candidates to late stages of discovery.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing, and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease, and Alzheimer’s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionized the treatment options, but there remains a large unmet need for new and innovative therapeutics. Focus on R&D is the most important pillar in Lundbeck’s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centers in Denmark and China.

LFB Biotechnologies SASU provides plasma-derived medicinal products. The firm undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The company was founded on September 21, 2006 and is headquartered in Courtaboeuf, France.

Medical & Biological Laboratories Co., Ltd. engages in the research, development, manufacture and sale of biological products. It operates through the Reagents and Investment segments. The Reagent segment supplies, manufactures, and sells clinical reagents and research reagents, and its related equipment and instruments. The Investment segment deals with investments on bio-related enterprises and mediates technical partnership. The company was founded on August 23, 1969 and is headquartered in Nagoya, Japan.

MDS Nordion, Inc. use to export medical isotopes, radio therapeutics and related technologies. Its products and services were used in hospitals, clinics, large medical supply companies, biotechnology, pharmaceutical companies, food processors and manufacturers. The company was founded in 1946 and was headquartered in Ottawa, Canada.

Shenzhen Baoshuntai Biomedical Co., Ltd., established on 2010-09-10, Business scope includes general business items:computer software,Information system software development,Sales;Information system design,integrated,Operation and Maintenance;Information Technology Consulting.,The licensing program is:Technical development of biological high-tech products,production and sales;Research, development and sales of medical electronic devices;Research and development of veterinary drugs,production and sales;yolk immunoglobulin(IgY)research and development,production and sales;Medical device production,operate(one type,Class II,Three categories);medical clothing,Face mask,hat,Production of shoe covers for medical protective products,operate;disinfect robot,Production of intelligent inspection robots,operate;Production of disinfection products,operate;food sales(Only sell prepackaged food).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Dyax Corp. (Dyax) is a biopharmaceutical company focused on the discovery, development and commercialization of biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company's lead product, DX-88, has been approved under the brand name KALBITOR (ecallantide) by the United States Food and Drug Administration (FDA) for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. The Company commercializes KALBITOR on its own in the United States. In addition to its approved commercial use for HAE in the United States, the Company is also developing DX-88 through collaborations in other indications. These include use of DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals (Cubist), and for treatment of retinal diseases in collaboration with Fovea Pharmaceuticals (Fovea), which was acquired by sanofi-aventis during the year ended December 31, 2009.